Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus clausii
- Development stage
- Phase 4
- Lead developer
- Sanofi
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus clausii is an orally administered spore-forming probiotic bacterium used as a therapeutic microbial product to help restore intestinal microbial balance, particularly during or after antibiotic exposure and in acute infectious diarrhea. Clinical-trial and publication evidence identifies it most prominently in Sanofi's Enterogermina program, including randomized studies in children with acute diarrhea, antibiotic-associated diarrhea prevention, and other gastrointestinal conditions. Its activity is not mediated through a single human receptor target; rather, proposed mechanisms include transient gut colonization, competitive effects on intestinal microbes, support of microbiota recovery, and immunomodulatory and antimicrobial effects of probiotic spores and metabolites. Commercial products exist both as pharmaceutical/consumer probiotic suspensions of spores and as region-specific marketed products from companies including Sanofi and LiveSpo Global.
- Brand names
- EnterogerminaErcefloraLiveSpo CLAUSYBiale Germin ForteBacipore
- Other names
- Bacillus clausii sporesBacillus clausii probiotic strainBacillus clausii O/CBacillus clausii N/RBacillus clausii SINBacillus clausii T
02
Targets
Shigella spp. (Shigella species)
Beyond the preview
Go deeper on bacillus clausii.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus clausii.